Abstract
Background:
People with diabetes mellitus (DM) have a higher risk for drug-resistant tuberculosis (DR-TB). DR-TB patients with comorbidity of DM were also vulnerable to experience adverse effects of DR-TB treatment. Management of DR-TB with comorbidity of DM is complicated. Also, DM may affect TB response treatment and cause more adverse effects.Objectives:
This study was conducted on DR pulmonary TB (DR-PTB) patients to evaluate the effect of DM on adverse effects, especially renal function impairment and audiology impairment, as well as treatment outcomes due to treatment regimens containing kanamycin.Methods:
A retrospective study was conducted from 2016 to 2017 at Dr. Soetomo Hospital. Patients who received DR-TB regimens containing kanamycin were included in this study. HbA1c >7 was used to define DM. The adverse effects in this study were impaired renal function (increased serum creatinine) and audiology impairment.Results:
Patients who experienced increased serum creatinine were 28/82 (34.1%) with DM and 20/120 (16.7%) without DM, audiology impairment were 22/82 (26.8%) with DM and 19/120 (15.8%) without DM, and unfavorable outcome were 37/82 (45%) with DM and 46/120 (38%) without DM. Moreover, DM is associated with adverse effects and treatment outcomes. Patients with DM have a risk ratio (RR) for increased serum creatinine, audiology impairment, and unfavorable outcome with RR 2.049 (95% CI: 1.242 – 3.379), RR 1.694 (95% CI: 0.982 – 2.925), and RR 1.177 (95% CI: 0.847 – 1.636), respectively.Conclusions:
Diabetes mellitus increases the risk of adverse effects, increased serum creatinine, and audiology impairment. Also, it increases the risk of unfavorable treatment outcomes in patients with DR-PTB who receive DR-TB regimens containing kanamycin.Keywords
Drug-Resistant Pulmonary Tuberculosis Diabetes Mellitus Adverse Effects
1. Background
Multidrug-resistant tuberculosis (MDR-TB) is a public health crisis. Indonesia is one of 30 countries with the highest MDR/RR-TB cases in the world, with the number of incidences of MDR/RR TB 23,000 and the percentage of MDR TB is 91% (1). Drug-resistant tuberculosis (DR-TB) cases in Dr. Soetomo Hospital were 90 cases in 2012, 143 cases in 2013, 142 cases in 2014, and 140 cases in 2015 (2). The treatment of MDR-TB is challenging, especially for patients with comorbidities. The incidence of diabetes mellitus (DM) is increasing globally (3).
People with diabetes mellitus (DM) have a higher risk for DR-TB infection. Among patients with MDR-TB, DM is a common comorbidity, which was reported to be correlated with an increased risk of treatment failure and death in MDR-TB-treated patients and followed for 8–11 years (4). Comorbidity of DM in MDR-TB treatment causes the worse adverse effect and treatment outcomes, increases the cost of treatment, promotes the MDR-TB transmission, and can also generate extensively drug-resistant TB (XDR-TB) (5). Diabetes mellitus may affect TB response treatment and cause more adverse effects. In some cases, adverse effects cause a changed DR-TB regimen and can also cause permanent discontinuation of the drug used due to adverse effects (6).
A greater bacillary load at the baseline was found in patients with DR-TB having comorbidity of DM, which caused a longer time to culture conversion. Diabetes mellitus caused a change in drug absorption and impaired renal or liver function in drug clearance (7). It may be hypothesized that DR-TB with DM increased the risk of an unfavorable outcome. Many studies from different countries suggested that there is a significantly higher risk of unfavorable outcomes in patients with DR-TB and DM (3, 4, 8, 9), while other studies reported different results that there was no correlation (10-13). Patients with DM have a higher risk of developing serious adverse effects of DR-TB treatment, such as nephrotoxicity and hypothyroidism (12).
2. Objectives
This study was conducted on DR Pulmonary TB (DR-PTB) patients to evaluate the effect of DM on specific adverse effects such as impaired renal function and audiology impairment, as well as to evaluate treatment outcome due to DR-TB regimens treatment to improve the treatment strategy of DR-TB with DM.
3. Methods
3.1. Study Design
This was a retrospective study conducted from 2016 to 2017. Study subjects were DR pulmonary TB patients in Dr. Soetomo Hospital, as a referral hospital for TB and DR-TB in east Indonesia. Patients with DR-TB receive DR-TB regimens containing kanamycin with normal renal and audiology functions at baseline tests were included in this study. Patients with DR-TB received nephrotoxic and ototoxic drugs, and patients with HIV comorbidity were excluded from this study.
3.2. Operational Definition
HbA1c >7 was used to define DM. The adverse effects in this study were impaired renal function (increased serum creatinine) and audiology impairment. Treatment outcomes were divided into favorable outcomes and unfavorable outcomes. Favorable outcomes were cure and treatment completion, while unfavorable outcomes were treatment failure, loss to follow-up, and death.
3.3. Audiometry and Renal Function Test
Serum creatinine levels were examined monthly as laboratory monitoring. Audiology impairment was based on an audiometry test using an automatic machine. Increased serum creatinine was above the normal range (0.6 – 1.3 mg/dL) according to the standard in Dr. Soetomo Hospital. Ototoxicity is diagnosed by comparing an initial audiogram -ideally obtained before initiation of ototoxic drugs- with hearing thresholds using serial audiograms (14). Audiology impairment was defined based on hearing-value according to American Speech-Language-Hearing Association (ASHA), audiometry test above 25 dB.
3.4. Data Analysis
Adverse effects and treatment outcomes were compared between DR-TB patients with DM and without DM. Adverse effects and treatment outcomes were analyzed using unadjusted relative risk (RR) and 95% confidence interval (95% CI). SPSS 21.0 was used for all statistical analyses.
4. Results
There were 202 patients with DR-TB in this study, consisted of 82/202 (40%) DR-TB patients with DM, and 120/202 (60%) of DR-TB patients without DM. Mean age of DR-TB patients with DM was 47.26 years old, and DR-TB patients without DM was 38.31 years old (Table 1).
Profile of Patients with DR-TB
| With DM, No. (%) | Without DM, No. (%) | Total | |
|---|---|---|---|
| Men | 40 (36.4) | 70 (63.6) | 110 |
| Women | 42 (45.7) | 50 (54.3) | 92 |
| Age, mean ± SD (range) | 47.26 ± 8.818 (26-68) | 38.31 ± 11.061 (16-73) | 41.94 ± 11.098 (16-73) |
| RR-TB | 5 (41.7) | 7 (58.3) | 12 |
| MDR-TB | 66 (39.1) | 103 (60.9) | 169 |
| PRE XDR TB | 11 (52.4) | 10 (47.6) | 21 |
There were 28/82 (34.1%) DR-TB patients with DM and 20/120 (16.7%) DR-TB patients without DM who experienced increased serum creatinine. Patients with DM have a risk ratio (RR) for increased serum creatinine with RR 2.049 (95% CI: 1.242 - 3.379), as presented in Table 2.
Correlation Between DM and Increased Serum Creatinine
| Increased Serum Creatinine | Normal Serum Creatinine | Total | RR (95% CI) | |
|---|---|---|---|---|
| With DM, No. (%) | 28 (34.1) | 54 (65.9) | 82 | 2.049 (1.242 – 3.379 |
| Without DM, No. (%) | 20 (16.7) | 100 (83.3) | 120 |
There were 22/82 (26.8%) DR-TB patients with DM and 19/120 (15.8%) DR-TB without DM experienced audiology impairment. Patients with DM have a risk ratio (RR) for increased serum creatinine, audiology impairment with RR 1.694 (95% CI: 0.982 - 2.925) as presented in Table 3.
Patients with unfavorable outcomes (treatment failure, loss to follow-up, and death) were 37/82 (45%) patients with DM and 46/120 (38%) patients without DM. Our study revealed that patients with DM have a risk ratio for unfavorable outcomes with RR 1.177 (95% CI: 0.847 - 1.636) as presented in Table 4.
Correlation Between DM and Audiology Impairment
| Audiology Impairment | Normal Audiology | Total | RR (95% CI) | |
|---|---|---|---|---|
| With DM, No. (%) | 22 (26.8) | 60 (73.2) | 82 | 1.694 (0.982 – 2.925) |
| Without DM, No. (%) | 19 (15.8) | 101 (84.2) | 120 |
Treatment Outcome in Patients with DR-TB
| Unfavorable Outcome | Favorable Outcome | Total | RR (95% CI) | |
|---|---|---|---|---|
| With DM, No. (%) | 37 (45) | 45 (55) | 82 | 1.177 (0.847- 1.636) |
| Without DM, No. (%) | 46 (38) | 74 (62) | 120 |
5. Discussion
Of the 202 patients, there were 110 (54%) men and 92 (46%) women in this study. According to the WHO global TB report, there were 5.8 million men, 3.2 million women, and 1.0 million children who developed TB disease in 2017 (1). In Indonesia, TB is significantly more common among men than among women (15).
Aminoglycosides are often toxic to both the kidney (nephrotoxicity) and the inner ear (ototoxicity). Nephrotoxicity, however, is often reversible, while ototoxicity is generally permanent (16). Our study found that DM increases the risk for adverse effects and serum creatinine with RR 2.049 (95% CI: 1.242 - 3.379). Unregulated DM correlates with acute ketoacidosis and chronic complications, such as diabetic nephropathy, neuropathy, retinopathy, diabetic foot, and cardiovascular problems (17). Diabetes mellitus alters drug absorption and impairs renal or liver function in drug clearance (7). Amikacin, kanamycin, and other aminoglycosides are practically not metabolized by the human body and are excreted unchanged almost exclusively by glomerular filtration. Renal clearance may strongly affect the toxicity of aminoglycosides (18). Diabetes causes glomerular hyperfiltration, classically has been hypothesized to predispose to irreversible nephron damage, thereby contributing to initiation and progression of kidney disease in diabetes (19). A study in Mexico reported that the presence of DM was associated with an increased risk of serious adverse effects such as nephrotoxicity (OR = 6.5; 95% CI: 1.9 - 21.8) (12). The mechanisms by which aminoglycosides may alter the renal tubular function remain speculative. Available data suggest that the proximal tubular diseases (and acute kidney injury) might result from mitochondrial dysfunction. On the other hand, the loop of Henle/distal tubular injury may result from activation of the calcium-sensing receptor (20).
Our study demonstrated that audiology impairment in patients with DM was higher than patients without DM (26.8% Vs 15.8%). DM increased risk for audiology impairment. Torrico also reported that ototoxicity was higher in patients with DM compared to patients without DM (56% Vs 32%), with OR 2.8; 95% CI: 0.8 - 10.6 (12). The use of kanamycin in MDR-TB treatment causes the adverse effect of hearing loss in more than 25% of all patients in a prospective cohort (21). There are various theories of aminoglycoside ototoxicity, including oxidative stress and free radical formation (22), uptake and penetration of the aminoglycosides within the cochlear cells (23), and well as drug concentrations (24). The aminoglycosides used to treat DR-TB can cause irreversible hearing loss, as they destroy the outer hair cells in the cochlea. The exact pathophysiological mechanism is not entirely understood (25). Nevertheless, once the aminoglycosides are inside these cochlea cells, they start to generate reactive oxygen species, which is central to the destruction of these hair cells (22). Diabetes mellitus was significantly associated with ototoxicity in patients with DR-TB (26). A previous study reported that ototoxicity was found in 18/100 (18%) of patients with MDR-TB who received kanamycin. Ototoxicity was associated with comorbid conditions like DM and hypertension (27). Diabetes mellitus is closely linked to hearing damage. Both large and microscopic size blood vessels are affected in DM. Metabolic disorders, atherosclerotic changes, and microvessel diseases result in ischemia and hypoxia in neural tissues, leading to nerve damage. When such pathological changes involve the cochlea, and auditory nerve, cochlear and/or neural hearing loss follows (28).
Our study established that DM increased the risk for unfavorable outcomes with RR 1.177 (95% CI: 0.847 - 1.636). The unfavorable outcomes were 37/82 (45%) with DM and 46/120 (38%) without DM. Another study also reported that DM has a significant association (OR 3.578; 95% CI: 1.114 - 11.494) with the development of adverse effects. Diabetes mellitus is associated with treatment outcomes in pulmonary TB patients and adverse effects (29). Management of DR-TB is complicated. Second-line drugs (SLDs) used to treat DR-TB are less potent and costlier than first-line drugs (FLDs). Second-line drugs are also correlated with more adverse events and are less tolerated (30). Another study reported different results that DM was not associated with unfavorable outcomes in patients with DR-TB, while DR-TB and HIV co-infection, second-line drug resistance, and history of treatment in the private sector were more frequently associated with adverse outcomes (31). Diabetes mellitus did not correlate with DR-TB treatment outcomes, but DM in patients with DR-TB increased serious adverse effects to DR TB treatment, such as nephrotoxicity and hypothyroidism (12). Another study reported that DM correlated with the treatment outcome as well as adverse drug reaction incidence (29).
The limitations of the study are as follows: comorbidity of DM was defined based on baseline examination, and there were no data of regulated and non-regulated DM. Medical records also did not mention whether patients with DM were insulin-dependent. We also did not include variables which might also have an association with adverse effect and treatment outcomes in patients with DR-TB.
5.1. Conclusions
Diabetes mellitus increases the risk of adverse effects, serum creatinine, and audiology impairment. It also increases the risk of unfavorable treatment outcomes in patients with DR pulmonary TB who receive DR-TB regimens containing kanamycin.
References
-
1.
World Health Organization. WHO global tuberculosis report 2017. Geneva, Switzerland: WHO; 2018. Available from: https://www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf.
-
2.
Indonesia Ministry of Health. E-TB manager: tuberculosis management information system. 2019, [cited 22April 2019]. Available from: http://etbmanager.sitb.id.
-
3.
Reis-Santos B, Gomes T, Locatelli R, de Oliveira ER, Sanchez MN, Horta BL, et al. Treatment outcomes in tuberculosis patients with diabetes: a polytomous analysis using Brazilian surveillance system. PLoS One. 2014;9(7). e100082. [PubMed ID: 25003346]. [PubMed Central ID: PMC4086729]. https://doi.org/10.1371/journal.pone.0100082.
-
4.
Kang YA, Kim SY, Jo K, Kim HJ, Park S, Kim T, et al. Impact of diabetes on treatment outcomes and long-term survival in multidrug-resistant tuberculosis. Respiration. 2013;86(6):472-8. https://doi.org/10.1159/000348374.
-
5.
Liu Q, Li W, Xue M, Chen Y, Du X, Wang C, et al. Diabetes mellitus and the risk of multidrug resistant tuberculosis: a meta-analysis. Sci Rep. 2017;7(1):1090. [PubMed ID: 28439071]. [PubMed Central ID: PMC5430797]. https://doi.org/10.1038/s41598-017-01213-5.
-
6.
Zhang Y, Wu S, Xia Y, Wang N, Zhou L, Wang J, et al. Adverse events associated with treatment of multidrug-resistant tuberculosis in China: An ambispective cohort study. Med Sci Monit. 2017;23:2348-56. [PubMed ID: 28520704]. [PubMed Central ID: PMC5444822]. https://doi.org/10.12659/msm.904682.
-
7.
Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9(12):737-46. [PubMed ID: 19926034]. [PubMed Central ID: PMC2945809]. https://doi.org/10.1016/S1473-3099(09)70282-8.
-
8.
Chiang CY, Bai KJ, Lin HH, Chien ST, Lee JJ, Enarson DA, et al. The influence of diabetes, glycemic control, and diabetes-related comorbidities on pulmonary tuberculosis. PLoS One. 2015;10(3). e0121698. [PubMed ID: 25822974]. [PubMed Central ID: PMC4378948]. https://doi.org/10.1371/journal.pone.0121698.
-
9.
Odone A, Houben RM, White RG, Lonnroth K. The effect of diabetes and undernutrition trends on reaching 2035 global tuberculosis targets. Lancet Diabetes Endocrinol. 2014;2(9):754-64. [PubMed ID: 25194888]. https://doi.org/10.1016/S2213-8587(14)70164-0.
-
10.
Magee MJ, Kempker RR, Kipiani M, Tukvadze N, Howards PP, Narayan KM, et al. Diabetes mellitus, smoking status, and rate of sputum culture conversion in patients with multidrug-resistant tuberculosis: a cohort study from the country of Georgia. PLoS One. 2014;9(4). e94890. [PubMed ID: 24736471]. [PubMed Central ID: PMC3988137]. https://doi.org/10.1371/journal.pone.0094890.
-
11.
Magee MJ, Kempker RR, Kipiani M, Gandhi NR, Darchia L, Tukvadze N, et al. Diabetes mellitus is associated with cavities, smear grade, and multidrug-resistant tuberculosis in Georgia. Int J Tuberc Lung Dis. 2015;19(6):685-92. [PubMed ID: 25946360]. [PubMed Central ID: PMC4562412]. https://doi.org/10.5588/ijtld.14.0811.
-
12.
Muñoz-Torrico M, Caminero-Luna J, Migliori GB, D’Ambrosio L, Carrillo-Alduenda JL, Villareal-Velarde H, et al. Diabetes is associated with severe adverse events in multidrug-resistant tuberculosis. Arch Bronconeumol. 2017;53(5):245-50. https://doi.org/10.1016/j.arbr.2016.10.003.
-
13.
Leung CC, Yew WW, Mok TYW, Lau KS, Wong CF, Chau CH, et al. Effects of diabetes mellitus on the clinical presentation and treatment response in tuberculosis. Respirology. 2017;22(6):1225-32. [PubMed ID: 28244689]. https://doi.org/10.1111/resp.13017.
-
14.
Harris T, Bardien S, Schaaf HS, Petersen L, De Jong G, Fagan JJ. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. S Afr Med J. 2012;102(6 Pt 2):363-6. [PubMed ID: 22668907]. https://doi.org/10.7196/samj.4964.
-
15.
Indonesia Ministry of Health. The joint external TB monitoring mission (JEMM TB) Indonesia 2017. Indonesia: Indonesia Ministry of Health; 2017. Available from: https://www.who.int/docs/default-source/searo/indonesia/non-who-publications/2017-joint-external-tb-monitoring-system-indonesia.pdf?sfvrsn=a10eb522_2.
-
16.
Huth ME, Ricci AJ, Cheng AG. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol. 2011;2011:937861. [PubMed ID: 22121370]. [PubMed Central ID: PMC3202092]. https://doi.org/10.1155/2011/937861.
-
17.
Onuka O, Ahukanna J, Okebaram C, Dakum P, Agbaje A, Ibeziako V, et al. A case study of multi drug-resistant tuberculosis (MDR-TB), HIV and diabetes mellitus (dm) comorbidity: Triple pathology; challenges and prospects. Adv Infect Dis. 2017;7(3):70-9. https://doi.org/10.4236/aid.2017.73008.
-
18.
Sagwa EL, Ruswa N, Mavhunga F, Rennie T, Leufkens HG, Mantel-Teeuwisse AK. Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort. BMC Pharmacology and Toxicology. 2015;16(1). https://doi.org/10.1186/s40360-015-0036-7.
-
19.
Tonneijck L, Muskiet MH, Smits MM, van Bommel EJ, Heerspink HJ, van Raalte DH, et al. Glomerular hyperfiltration in diabetes: Mechanisms, clinical significance, and treatment. J Am Soc Nephrol. 2017;28(4):1023-39. [PubMed ID: 28143897]. [PubMed Central ID: PMC5373460]. https://doi.org/10.1681/ASN.2016060666.
-
20.
Scoglio M, Bronz G, Rinoldi PO, Faré PB, Betti C, Bianchetti MG, et al. Electrolyte and acid-base disorders triggered by aminoglycoside or colistin therapy: A systematic review. Antibiotics. 2021;10(2). https://doi.org/10.3390/antibiotics10020140.
-
21.
Heysell SK, Ahmed S, Rahman MT, Akhanda MW, Gleason AT, Ebers A, et al. Hearing loss with kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh. Eur Respir J. 2018;51(3). [PubMed ID: 29348152]. [PubMed Central ID: PMC6230246]. https://doi.org/10.1183/13993003.01778-2017.
-
22.
Poirrier AL, Pincemail J, Van Den Ackerveken P, Lefebvre PP, Malgrange B. Oxidative stress in the cochlea: an update. Curr Med Chem. 2010;17(30):3591-604. [PubMed ID: 20738243]. https://doi.org/10.2174/092986710792927895.
-
23.
Xie J, Talaska AE, Schacht J. New developments in aminoglycoside therapy and ototoxicity. Hear Res. 2011;281(1-2):28-37. [PubMed ID: 21640178]. [PubMed Central ID: PMC3169717]. https://doi.org/10.1016/j.heares.2011.05.008.
-
24.
Touw DJ, Westerman EM, Sprij AJ. Therapeutic drug monitoring of aminoglycosides in neonates. Clin Pharmacokinet. 2009;48(2):71-88. [PubMed ID: 19271781]. https://doi.org/10.2165/0003088-200948020-00001.
-
25.
Avent ML, Rogers BA, Cheng AC, Paterson DL. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity. Intern Med J. 2011;41(6):441-9. [PubMed ID: 21309997]. https://doi.org/10.1111/j.1445-5994.2011.02452.x.
-
26.
Sogebi OA, Adefuye BO, Adebola SO, Oladeji SM, Adedeji TO. Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy. Auris Nasus Larynx. 2017;44(4):404-10. [PubMed ID: 27832910]. https://doi.org/10.1016/j.anl.2016.10.005.
-
27.
Sharma V, Bhagat S, Verma B, Singh R, Singh S. Audiological evaluation of patients taking kanamycin for multidrug resistant tuberculosis. Iran J Otorhinolaryngol. 2016;28(86):203-8. [PubMed ID: 27429949]. [PubMed Central ID: PMC4930843].
-
28.
Xipeng L, Ruiyu L, Meng L, Yanzhuo Z, Kaosan G, Liping W. Effects of diabetes on hearing and cochlear structures. J Otology. 2013;8(2):82-7. https://doi.org/10.1016/s1672-2930(13)50017-1.
-
29.
Siddiqui AN, Khayyam KU, Sharma M. Effect of diabetes mellitus on tuberculosis treatment outcome and adverse reactions in patients receiving directly observed treatment strategy in india: A prospective study. Biomed Res Int. 2016;2016:7273935. [PubMed ID: 27642601]. [PubMed Central ID: PMC5013229]. https://doi.org/10.1155/2016/7273935.
-
30.
Sulaiman SAS, Khan AH, Ahmad N, Iqubal MS, Muttalif AR, Hassali MA. Impact of diabetes mellitus on treatment outcomes of tuberculosis patients in tertiary care setup. Am J Med Sci. 2013;345(4):321-5. [PubMed ID: 23531965]. https://doi.org/10.1097/MAJ.0b013e318288f8f3.
-
31.
Latif A, Ghafoor A, Wali A, Fatima R, ul-Haq M, Yaqoob A, et al. Did diabetes mellitus affect treatment outcome in drug-resistant tuberculosis patients in Pakistan from 2010 to 2014? Int Tuberc Lung Dis. 2018;8(1):14-9. https://doi.org/10.5588/pha.17.0098.